Skip to main content

Table 1 General patient characteristics

From: Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study

  SScPAH
N= 5
IPAH
N= 9
PVOD
N= 6
Control
N= 5
Age, yrs 51 (32 to 60) 53 (23 to 59) 33 (23 to 59) 33 (24 to 76)
Male/Female (n) 1/4 2/7 3/3 5/0
Antibody (Ab) profile anti-centromere:
5 (100%)
0 0  
Disease duration of PAH at time of death/biopsy (yrs) 1 (0.1 to 4.0) 2.6 (0.8 to 9.0) 1.9 (0.08 to 5.0)  
Therapy at time of
death/biopsy
    
Monotherapy:     
prostacycline 3 6 4  
PDE-5 inhibitor 0 1 0  
ERA 0 1 2  
Combination therapy:     
Prostacycline+ERA+   0 0  
PDE-5 inibitor (n) 1    
ERA+PDE-5 inhibitor (n) 1 0 0  
ERA+prostacycline (n) 0 1 0  
Limited cutaneous SSc, n (%) 5 (100%)    
SSc disease duration, yrs * 2 (1 to 34)    
Raynaud phenomenon duration, yrs 13 (1 to 40)    
  1. Values expressed as median (range) or otherwise as stated. * Since first non-Raynaud symptom, at time of diagnosis of pulmonary arterial hypertension.
  2. ABS, atrial balloon septostomia; ERA, endothelin receptor antagonist; IPAH, idiopathic PAH; PDE-5, phosphodiesterase 5; PVOD, pulmonary veno-occlusive disease; SScPAH, systemic sclerosis-associated pulmonary arterial hypertension (PAH).